Evidence map›Paper›PMID 36510619›Full record

ArticleInternational journal of nanomedicine2022

Combined Ibuprofen-Nanoconjugate Micelles with E-Selectin for Effective Sunitinib Anticancer Therapy.

Xianhu Zeng, Yi Teng, Chunrong Zhu, Zhipeng Li, Tian Liu, Yong Sun, Shangcong Han

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xianhu ZengDepartment of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, People's Republic of China.
Yi TengDepartment of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, People's Republic of China.
Chunrong ZhuDepartment of Pharmacy Intravenous Admixture Service, Weifang Maternal and Child Health Hospital, Weifang, People's Republic of China.
Zhipeng LiDepartment of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, People's Republic of China.ORCID 0000-0001-8154-6221
Tian LiuDepartment of Urology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
Yong SunDepartment of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, People's Republic of China.ORCID 0000-0003-0365-1151
Shangcong HanDepartment of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, People's Republic of China.ORCID 0000-0001-9195-7972
Qingdao University · CNWeifang Maternity and Child Care Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Sunitinib, a first-line therapy with a certain effect, was utilized in the early stages of renal cell carcinoma treatment. However, its clinical toxicity, side effects, and its limited bioavailability, resulted in inadequate clinical therapeutic efficacy. Building neoteric, simple, and safe drug delivery systems with existing drugs offers new options. Therefore, we aimed to construct a micelle to improve the clinical efficacy of sunitinib by reusing ibuprofen. Methods: We synthesized the sialic acid-poly (ethylene glycol)-ibuprofen (SA-PEG-IBU) amphipathic conjugate in two-step reaction. The SA-PEG-IBU amphiphilic conjugates can form into stable SPI nanomicelles in aqueous solution, which can be further loaded sunitinib (SU) to obtain the SPI/SU system. Following nanomicelle creation, sialic acid exposed to the nanomicelle surface can recognize the overexpressed E-selectin receptor on the membrane of cancer cells to enhance cellular uptake. The properties of morphology, stability, and drug release about the SPI/SU nanomicelles were investigated. Confocal microscopy and flow cytometry were used to assess the cellular uptake efficiency of nanomicelles in vitro. Finally, a xenograft tumor model in nude mice was constructed to investigate the body distribution and tumor suppression of SPI/SU in vivo. Results: The result showed that SPI nanomicelles exhibited excellent tumor targeting performance and inhibited the migration and invasion of tumor cell in vitro. The SPI nanomicelles can improve the accumulation of drugs in the tumor site that showed effective tumor inhibition in vivo. In addition, H&E staining and immunohistochemical analysis demonstrated that the SPI/SU nanomicelles had a superior therapeutic effect and lower biotoxicity. Conclusion: The SPI/SU nanomicelles displayed excellent anti-tumor ability, and can suppress the metastasis of tumor cell by decreasing the expression of Cyclooxygenase-2 due to the ibuprofen, providing an optimistic clinical application potential by developing a simple but safe drug delivery system.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAnimalsCell Line, TumorDrug CarriersHumansIbuprofenMiceMicellesMice, NudeN-Acetylneuraminic AcidNanoconjugatesPolyethylene GlycolsSunitinibDrug CarriersIbuprofenMicellesN-Acetylneuraminic AcidNanoconjugatesPolyethylene GlycolsSunitinibanti-tumor therapyibuprofenkidney cancernanomicellessialic acidsunitinib

Identifiers

PMID36510619
PMCPMC9740013
OpenAlexW4310869652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.